NYSE$ELV

Elevance Health Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Anthem reported strong financial performance in the second quarter of 2021 and raised full-year outlook.

Anthem, Inc. reported a 14.1% increase in operating revenue to $33.3 billion and GAAP net income of $7.25 per share for the second quarter of 2021. Medical enrollment reached 44.3 million members, and the company raised its full-year adjusted net income outlook to greater than $25.50 per share.

  • GAAP net income was $7.25 per share, including net positive adjustment items of $0.22 per share; adjusted net income was $7.03 per share.
  • Operating revenue grew by 14.1% over the prior quarter to $33.3 billion, or 15.8% adjusted for the repeal of the health insurance tax.
  • Medical enrollment increased by 1.9 million members year over year and 820 thousand members in the second quarter to 44.3 million members.
  • Full year adjusted net income outlook raised from greater than $25.10 per share to greater than $25.50 per share.

Headline financials

Total Revenue

$33.9B

Previous: $29.3B+15.7%
EPS (adj)

$7.03

Previous: $9.20-23.6%
Total Medical Membership

44.3M

Previous: 42.5M+4.2%
Capital Expenditures

-$489M

Previous: -$437M-11.9%
Free Cash Flow

$1.3B

Previous: $1.84B-29.1%
Net Income

$1.79B

Previous: $2.28B-21.2%
Operating Income

$2.08B

Previous: $3.36B-38.1%
Gross Profit

$31.2B

Previous: $27B+15.5%
Cash & Equivalents

$5.26B

Previous: $6.03B-12.8%
Total Assets

$96.1B

Previous: $88B+9.2%
Stock-Based Comp

$69M

Previous: $67M+3.0%

Revenue & EPS history

Elevance Health · Revenue · Quarterly

$33.9B

Q2 2021+15.7%vs Q2 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Elevance Health · $62B total across 4 segments · Q2 2026

  • Health Benefits
    $42.7B—
  • CarelonRx
    $11.3B—
  • Carelon Services
    $7.98B—
  • Corporate & Other
    $6M—

Forward guidance

Anthem expects GAAP net income to be greater than $24.89 per share and adjusted net income to be greater than $25.50 per share for the full year 2021. Medical membership is expected to be in the range of 44.8 - 45.3 million and operating revenue is expected to be approximately $137.1 billion.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-0.1%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+2.4%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+11.1%

Q4 2018

Best reaction

-15.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026———
Q1 2026+2.3%+8.5%+20.3%
Q4 2025+5.1%+5.9%-0.9%
Q3 2025-1.1%-3.3%-11.3%
Q2 2025+0.3%+6.0%+5.9%
Q1 2025+2.1%+3.7%-5.5%
Q4 2024+2.9%+3.8%-1.4%
Q3 2024-15.0%-15.5%-19.4%
Q2 2024-8.7%-8.9%-1.7%
Q1 2024+4.1%+4.7%+7.6%
Q4 2023+1.8%+3.0%+8.9%
Q3 2023-0.6%-3.0%-0.6%
Q2 2023+7.2%+6.2%+4.3%
Q1 2023-5.8%-4.2%-5.2%
Q4 2022+3.6%+2.2%-0.1%
Q3 2022+2.0%+10.1%+3.6%
Q2 2022-7.6%-5.3%+1.2%
Q1 2022+1.1%-2.0%-4.7%
Q4 2021-0.8%+0.4%+3.3%
Q3 2021+9.3%+10.4%+5.5%
Q2 2021-1.4%-2.9%-3.1%
Q1 2021-0.5%-1.1%+3.7%
Q4 2020-3.8%-6.4%-3.0%
Q3 2020-8.6%-6.9%+4.7%
Q2 2020+4.5%+2.1%+4.5%
Q1 2020+4.7%+1.0%+9.7%
Q4 2019-8.4%-8.2%-11.4%
Q3 2019-0.3%+2.9%+12.1%
Q2 2019-2.9%-1.4%-13.9%
Q1 2019+2.1%+6.2%+10.6%
Q4 2018+11.1%+11.6%+12.8%
Q3 2018+0.2%+1.4%+9.3%
Q2 2018+0.4%+2.5%+7.8%
Q1 2018+5.3%+4.9%+3.3%
Q4 2017+0.2%-5.3%-4.3%
Q3 2017+6.0%+7.3%+12.9%
Q2 2017-3.7%-2.3%+1.1%
Q1 2017+3.4%+3.9%+6.2%
Q4 2016+2.3%+1.7%+7.7%
Q3 2016+2.2%+5.2%+23.6%
Q2 2016-3.4%-7.3%-9.2%
Q1 2016-2.1%——
Q4 2015-8.2%——
Q3 2015-2.3%——
Q2 2015+0.4%——
Q1 2015-2.1%——
Q4 2014-0.5%——
Q3 2014———
Q2 2014———
Q1 2014———
Q4 2013———
Q3 2013———
Q2 2013———
Q1 2013———
Q4 2011———
Q4 2012———
Q3 2012———
Q2 2012———
Q1 2012———
Q3 2011———
Q2 2011———
Q1 2011———
Q4 2010———
Q3 2010———
Q2 2010———
Q1 2009———
Q1 2010———
Q4 2007———
Q4 2009———
Q3 2009———
Q3 2008———
Q2 2009———
Q4 2008———
Q2 2008———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro